【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 18
2 Introduction 19
2.1 Auto-Immune Diseases Overview 19
3 Products under Development 20
3.1 Auto-Immune Diseases – Pipeline Products by Stage of Development 20
3.2 Auto-Immune Diseases – Pipeline Products by Territory 21
3.3 Auto-Immune Diseases – Pipeline Products by Regulatory Path 22
3.4 Auto-Immune Diseases – Pipeline Products by Estimated Approval Date 23
4 Auto-Immune Diseases – Pipeline Products under Development by Companies 24
4.1 Auto-Immune Diseases Companies – Pipeline Products by Stage of Development 24
4.2 Auto-Immune Diseases – Pipeline Products by Stage of Development 28
5 Auto-Immune Diseases Companies and Product Overview 35
5.1 Adaptive Biotechnologies Corporation Company Overview 35
5.1.1 Adaptive Biotechnologies Corporation Pipeline Products & Ongoing Clinical Trials Overview 35
5.2 Agena Bioscience, Inc Company Overview 36
5.2.1 Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 36
5.3 Albert-Ludwigs-Universitat Freiburg Company Overview 37
5.3.1 Albert-Ludwigs-Universitat Freiburg Pipeline Products & Ongoing Clinical Trials Overview 37
5.4 Alere Inc. Company Overview 40
5.4.1 Alere Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.5 Amarantus Bioscience Holdings, Inc. Company Overview 43
5.5.1 Amarantus Bioscience Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.6 Amdix B.V. Company Overview 46
5.6.1 Amdix B.V. Pipeline Products & Ongoing Clinical Trials Overview 46
5.7 Analyticon Biotechnologies AG Company Overview 47
5.7.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 47
5.8 apDia n.v. Company Overview 48
5.8.1 apDia n.v. Pipeline Products & Ongoing Clinical Trials Overview 48
5.9 Autoimmune Technologies, LLC Company Overview 49
5.9.1 Autoimmune Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 49
5.10 Beckman Coulter, Inc. Company Overview 55
5.10.1 Beckman Coulter, Inc. Pipeline Products & Ongoing Clinical Trials Overview 55
5.11 BG Medicine, Inc. Company Overview 57
5.11.1 BG Medicine, Inc. Pipeline Products & Ongoing Clinical Trials Overview 57
5.12 Biocortech Company Overview 59
5.12.1 Biocortech Pipeline Products & Ongoing Clinical Trials Overview 59
5.13 Biogen, Inc. Company Overview 60
5.13.1 Biogen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.14 Biomedal S.L. Company Overview 62
5.14.1 Biomedal S.L. Pipeline Products & Ongoing Clinical Trials Overview 62
5.15 Biomerica, Inc. Company Overview 66
5.15.1 Biomerica, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
5.16 Bionure Farma, S.L. Company Overview 70
5.16.1 Bionure Farma, S.L. Pipeline Products & Ongoing Clinical Trials Overview 70
5.17 Bio-Rad Laboratories, Inc. Company Overview 71
5.17.1 Bio-Rad Laboratories, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71
5.18 BioRap Technologies Ltd. Company Overview 73
5.18.1 BioRap Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 73
5.19 Boston University Company Overview 74
5.19.1 Boston University Pipeline Products & Ongoing Clinical Trials Overview 74
5.20 CareDx, Inc. Company Overview 75
5.20.1 CareDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
5.21 CD Diagnostics, Inc. Company Overview 77
5.21.1 CD Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 77
5.22 Chronix Biomedical, Inc. Company Overview 78
5.22.1 Chronix Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
5.23 Co-Diagnostics HBDC, Inc. Company Overview 81
5.23.1 Co-Diagnostics HBDC, Inc. Pipeline Products & Ongoing Clinical Trials Overview 81
5.24 Crescendo Bioscience, Inc. Company Overview 82
5.24.1 Crescendo Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82
5.25 Digna Biotech, S.L. Company Overview 86
5.25.1 Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 86
5.26 Durin Technologies, Inc. Company Overview 90
5.26.1 Durin Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 90
5.27 Enterome Bioscience SA Company Overview 91
5.27.1 Enterome Bioscience SA Pipeline Products & Ongoing Clinical Trials Overview 91
5.28 Ezose Sciences Inc. Company Overview 93
5.28.1 Ezose Sciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 93
5.29 Flamentera AG Company Overview 94
5.29.1 Flamentera AG Pipeline Products & Ongoing Clinical Trials Overview 94
5.30 Genalyte, Inc. Company Overview 95
5.30.1 Genalyte, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.31 Genentech, Inc. Company Overview 96
5.31.1 Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 96
5.32 GeNeuro SA Company Overview 99
5.32.1 GeNeuro SA Pipeline Products & Ongoing Clinical Trials Overview 99
5.33 Glycominds Ltd. Company Overview 101
5.33.1 Glycominds Ltd. Pipeline Products & Ongoing Clinical Trials Overview 101
5.34 Grifols, S.A. Company Overview 102
5.34.1 Grifols, S.A. Pipeline Products & Ongoing Clinical Trials Overview 102
5.35 Hannover Medical School Company Overview 104
5.35.1 Hannover Medical School Pipeline Products & Ongoing Clinical Trials Overview 104
5.36 Helmholtz Centre for Infection Research Company Overview 105
5.36.1 Helmholtz Centre for Infection Research Pipeline Products & Ongoing Clinical Trials Overview 105
5.37 HOB Biotech Group Co., Ltd. Company Overview 106
5.37.1 HOB Biotech Group Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 106
5.38 Hospital for Special Surgery Company Overview 107
5.38.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 107
5.39 Hycor Biomedical Inc. Company Overview 108
5.39.1 Hycor Biomedical Inc. Pipeline Products & Ongoing Clinical Trials Overview 108
5.40 Ignyta, Inc. Company Overview 110
5.40.1 Ignyta, Inc. Pipeline Products & Ongoing Clinical Trials Overview 110
5.41 ImmusanT, Inc. Company Overview 114
5.41.1 ImmusanT, Inc. Pipeline Products & Ongoing Clinical Trials Overview 114
5.42 Innobiochips Company Overview 115
5.42.1 Innobiochips Pipeline Products & Ongoing Clinical Trials Overview 115
5.43 INOVA Diagnostics, Inc. Company Overview 116
5.43.1 INOVA Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 116
5.44 Institut National de la Sante et de la Recherche Medicale Company Overview 126
5.44.1 Institut National de la Sante et de la Recherche Medicale Pipeline Products & Ongoing Clinical Trials Overview 126
5.45 Is Diagnostics Company Overview 127
5.45.1 Is Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 127
5.46 LineaGen, Inc. Company Overview 128
5.46.1 LineaGen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 128
5.47 Lophius Biosciences GmbH Company Overview 129
5.47.1 Lophius Biosciences GmbH Pipeline Products & Ongoing Clinical Trials Overview 129
5.48 Louisville Bioscience, Inc. Company Overview 130
5.48.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 130
5.49 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Company Overview 134
5.49.1 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Pipeline Products & Ongoing Clinical Trials Overview 134
5.50 Medica Corporation Company Overview 135
5.50.1 Medica Corporation Pipeline Products & Ongoing Clinical Trials Overview 135
5.51 Metabolomic Technologies Inc. Company Overview 138
5.51.1 Metabolomic Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 138
5.52 Metanomics Health GmbH Company Overview 142
5.52.1 Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 142
5.53 MSDx, Inc. Company Overview 143
5.53.1 MSDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 143
5.54 Myriad Genetics, Inc. Company Overview 147
5.54.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 147
5.55 Nanosphere, Inc. Company Overview 149
5.55.1 Nanosphere, Inc. Pipeline Products & Ongoing Clinical Trials Overview 149
5.56 Neuro Vigor, LLC Company Overview 151
5.56.1 Neuro Vigor, LLC Pipeline Products & Ongoing Clinical Trials Overview 151
5.57 Northwestern University Company Overview 152
5.57.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 152
5.58 NoToPharm s.r.l. Company Overview 154
5.58.1 NoToPharm s.r.l. Pipeline Products & Ongoing Clinical Trials Overview 154
5.59 NOWDiagnostics Company Overview 162
5.59.1 NOWDiagnostics Pipeline Products & Ongoing Clinical Trials Overview 162
5.60 OmniBiome Therapeutics Inc. Company Overview 163
5.60.1 OmniBiome Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview 163
5.61 One Way Liver Genomics, S.L. Company Overview 164
5.61.1 One Way Liver Genomics, S.L. Pipeline Products & Ongoing Clinical Trials Overview 164
5.62 OPKO Health, Inc. Company Overview 166
5.62.1 OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 166
5.63 Oxford Gene Technology Limited Company Overview 168
5.63.1 Oxford Gene Technology Limited Pipeline Products & Ongoing Clinical Trials Overview 168
5.64 Oxford Immunotec Limited Company Overview 169
5.64.1 Oxford Immunotec Limited Pipeline Products & Ongoing Clinical Trials Overview 169
5.65 Pediatric Bioscience, LLC Company Overview 170
5.65.1 Pediatric Bioscience, LLC Pipeline Products & Ongoing Clinical Trials Overview 170
5.66 Progentec Diagnostics, Inc. Company Overview 171
5.66.1 Progentec Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 171
5.67 Protagen AG Company Overview 172
5.67.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 172
5.68 ProteinLogic Ltd Company Overview 182
5.68.1 ProteinLogic Ltd Pipeline Products & Ongoing Clinical Trials Overview 182
5.69 Quanterix Corporation Company Overview 183
5.69.1 Quanterix Corporation Pipeline Products & Ongoing Clinical Trials Overview 183
5.70 Regulus Therapeutics Inc. Company Overview 184
5.70.1 Regulus Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview 184
5.71 Rice University Company Overview 186
5.71.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 186
5.72 Roche Diagnostics International Ltd. Company Overview 187
5.72.1 Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 187
5.73 Shuwen Biotech Co. Ltd. Company Overview 193
5.73.1 Shuwen Biotech Co. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 193
5.74 Singulex, Inc. Company Overview 194
5.74.1 Singulex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 194
5.75 SomaLogic, Inc. Company Overview 195
5.75.1 SomaLogic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 195
5.76 Southern Illinois University Carbondale Company Overview 196
5.76.1 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 196
5.77 SQI Diagnostics Inc. Company Overview 198
5.77.1 SQI Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 198
5.78 The Johns Hopkins University Company Overview 207
5.78.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 207
5.79 The Walter and Eliza Hall Institute of Medical Research Company Overview 210
5.79.1 The Walter and Eliza Hall Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 210
5.80 TheraDiag SA Company Overview 211
5.80.1 TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 211
5.81 Thermo Fisher Scientific Inc. Company Overview 213
5.81.1 Thermo Fisher Scientific Inc. Pipeline Products & Ongoing Clinical Trials Overview 213
5.82 Toscana Biomarkers Srl Company Overview 237
5.82.1 Toscana Biomarkers Srl Pipeline Products & Ongoing Clinical Trials Overview 237
5.83 Univalue Valorizacion, S.L. Company Overview 243
5.83.1 Univalue Valorizacion, S.L. Pipeline Products & Ongoing Clinical Trials Overview 243
5.84 University of California, San Francisco Company Overview 244
5.84.1 University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview 244
5.85 University of Chicago Company Overview 247
5.85.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 247
5.86 University of Colorado Company Overview 248
5.86.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 248
5.87 University of Florida Company Overview 249
5.87.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 249
5.88 University of Manchester Company Overview 250
5.88.1 University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 250
5.89 University of Oxford Company Overview 252
5.89.1 University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 252
5.90 University of Pecs Company Overview 256
5.90.1 University of Pecs Pipeline Products & Ongoing Clinical Trials Overview 256
5.91 University Rovira i Virgili Company Overview 257
5.91.1 University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview 257
5.92 US Biomarkers, Inc. Company Overview 258
5.92.1 US Biomarkers, Inc. Pipeline Products & Ongoing Clinical Trials Overview 258
5.93 Washington University in St. Louis Company Overview 259
5.93.1 Washington University in St. Louis Pipeline Products & Ongoing Clinical Trials Overview 259
5.94 XAir Diagnostics B.V. Company Overview 260
5.94.1 XAir Diagnostics B.V. Pipeline Products & Ongoing Clinical Trials Overview 260
5.95 XEPTAGEN SpA Company Overview 261
5.95.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 261
5.96 Yale University Company Overview 262
5.96.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 262
6 Auto-Immune Diseases- Recent Developments 263
7 Appendix 292
7.1 Methodology 292
7.2 About GlobalData 294
7.3 Contact Us 295
7.4 Disclaimer 295
【レポート販売概要】
■ タイトル:世界の自己免疫疾患用装置開発動向:医療機器パイプライン分析2015■ 英文:Auto-Immune Diseases - Medical Devices Pipeline Assessment, 2015
■ 発行日:2016年1月5日
■ 調査会社:GlobalData
■ 商品コード:GDME0148EPD
■ 調査対象地域:グローバル
- 神経疾患治療法の世界市場2019-2023Global Neurologic Disorders Therapeutics Market: About this market Technavio’s neurologic disorders therapeutics market analysis considers sales from both CNS and PNS. Our analysis also considers the sales of neurologic disorders therapeutics in Asia, Europe, North America, and ROW. In 2018, the CNS segment had a significant market share, and this trend is expected to continue over the forecast pe …
- マテハン機器の世界市場:AGV(無人搬送車)、ASRS、自動クレーン、ロボット装置、自動コンベヤー、仕分けシステムThe automated material handling equipment market is expected to reach USD 44.68 Billion by 2022, at a CAGR of 7.9% between 2016 and 2022. The growth of this market is propelled by the increasing demand for automated solutions, advancements in technology; need to ensure a safe working environment, and reduction in labor cost through advanced robotics. Unit load material handling system is estimated …
- 世界のデータセンター統合インフラシステム市場:Global Data Center Integrated Infrastructure Systems Market 2014-2018TechNavio's analysts forecast the Global Data Center Integrated Infrastructure Systems market to grow at a CAGR of 51.84 percent over the period 2014-2018. One of the key factors contributing to this market growth is the increased deployment of data centers. The Global Data Center Integrated Infrastructure Systems market has also been witnessing the transition to SDN solutions. However, the concer …
- 塩素酸ナトリウムの世界市場2019-2023About this market The increasing demand for sodium chlorate in the US will drive the sodium chlorate market growth in the forthcoming years. The increasing demand for paper and paper products in the US is expected to fuel the growth of the market. As pulp and paper manufacturing companies mainly consumed sodium chlorate for producing chlorine oxide. Furthermore, in the mining industry, sodium chlo …
- ブレース/支持具/補綴具:企業動向Braces and Supports and Prosthetic Devices - Current and Future Players Summary The global orthotics and prosthetics (O&P) market, which includes braces and supports and prosthetic devices, is an expansive market covering a broad range of indications. Braces and supports, external devices that provide support to joints and weakened musculoskeletal groups to facilitate function and healing, are uti …
- クラウド型VDIの世界市場:導入別(民間、公的、複合型)、最終用途別(政府、ヘルスケア、テレコム・IT、教育、その他)、地域別予測Global Cloud-based VDI Market to reach USD XXX billion by 2025. Global Cloud-based VDI Market valued approximately USD XXX billion in 2016 is forecasted to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The major factors speculated to augment the markets are increase in adoption of cloud-based solutions Rise in demand for virtualization Increase in adoption of …
- 安全針の世界市場:アクティブ安全針、パッシブ安全針The safety needles market accounted for $1,609 million in 2018, and is expected to reach $3,009 million by 2026, registering a CAGR of 8.1% from 2019 to 2026. Safety needle is a hollow, cylindrical needle bearing a puncturing point at the tip, which is attached to a syringe. It is used across medical settings in different applications such as drug delivery, vaccination, and blood specimen collecti …
- 陽イオン界面活性剤の世界市場2019-2023About this market Developing economies significantly to the global cationic surfactant market. Many OEMs of surfancts are shifting their manufacturing activities to these countries because of factors such as easy availability of raw materials, land, cost- effective labor and many more. These increasing population and industrialization in developing countries are likely to drive the consumption of …
- 直角座標ロボットの世界市場2015-2019About Cartesian robots Cartesian robots contains three prismatic joints whose axes are coextensive with a Cartesian coordinate system. Its working is based on an overhead grid that makes it free up floor space, and is primarily used to provide quick and accurate solutions related to material handling applications. It consists of a work envelope that is rectangular in shape. The work envelope depen …
- ラグジュアリーセグメント用自動運転車の世界市場予測(~2030年)“Increasing demand for luxury vehicles is set to drive the autonomous vehicle market for luxury segment”The global autonomous vehicle market for luxury segment is projected to be 27,906 units in 2025 and is projected to grow to 126,774 units by 2030, at a CAGR of 35.35%. Increasing accident fatalities coupled with rising concern for vehicle safety and security have accentuated the need for the dev …
- カーボンフットプリント(CFP)管理の世界市場予測(~2021年)MarketsandMarkets forecasts the carbon footprint management market size to grow from USD 7.76 Billion in 2016 to USD 12.94 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of 10.8%. Mandatory regulations & policies, increasing concern for reducing carbon footprints, rising prices of energy sources, targeting a sustainable future are some of the key factors driving the CFM market. The carbo …
- コーンビーム断層撮影法(CBCT) /コーンビーム画像化の世界市場予測(~2021):用途別(歯科(口腔および顎顔面外科手術、インプラント、矯正歯科、歯内治療)、患者の姿勢別(立ち姿勢/座り姿勢、着席、仰向け)、エンドユーザー別(病院、健康保険適用外開業医)The global CBCT/Cone beam imaging market is expected to reach USD 801.2 million by 2021 from USD 494.4 million in 2016, at a CAGR of 10.1% during the forecast period (2016-2021). Growth of this market is primarily driven by increasing prevalence of dental disorders, growth in geriatric population, growing demand for cosmetic dentistry, and expanding applications of CBCT systems. However, the high …
- グーグルVS競合企業:コマース市場-ウォレット・システム(Google vs. Competitors: Commerce Market ? Wallet Systems)A battle is raging in the mobile commerce arena in the area of mobile payments. Google is battling against others literally for (electronic) wallet share. The stakes are high because whomever wins the battle for wallet share will have a huge advantage when it comes to actual mobile commerce. Payment solutions can be categorized on the basis of the payment settlement methods, which are instant-paid …
- カーボンナノチューブ(CNT)の世界市場予測(~2023年)The carbon nanotubes market is expected to grow at a CAGR of 16.70% between 2018 and 2023. The carbon nanotubes market is estimated to grow from USD 4.55 billion in 2018 to USD 9.84 billion by 2023, at a CAGR of 16.70%. Growing demand from applications, such as advanced materials, electronics & semiconductors, chemical & polymers, batteries & capacitors, energy, aerospace & defense, and medical, i …
- 世界の小水力発電産業分析:Analyzing the Global Small Hydropower IndustrySmall hydropower gives a higher return on investment due to the low capital investment and operational and maintenance costs. Small hydropower plants are easier to construct as the designs are simpler and hence the costs are lower as well. China is the largest market for small hydropower in the world. The small hydropower market in China is driven by rural electrification programs of the Chinese g …